Company

Purpose

Anonymous Data Shared

When collaboration happened

Epigemonics

Validation of a new technique for improved sensitivity of lung cancer diagnosis in bronchial lavage samples

None – data analysed in-house and results shared.

2010 – 2012

Oxford Gene Technologies

Investigating our ability to find useful DNA mutations routinely collected tumour histology samples (e.g. that might help target treatment or aid prognosis).

None – data analysed in-house and results shared.

2013 – 2015

Company I*

Investigating new technology to find useful DNA mutations in blood samples

Cancer diagnosis (type and stage)

2015 – 2017

Company B*

Investigating the potential new technologies for cancer detection based on metabolites in blood

Risk profile and disease status

2016 – 2020

Company J*

 

Grant support for lung cancer research collaboration on early detection and prevention

Risk profile and disease status

2018 – 2022

Company R*

Grant support to investigate protein biomarkers for improved diagnosis of lung cancer

None – data analysed in-house and results shared.

2020 – 2021

* for reasons of confidentiality and commercial sensitivity, some names are withheld until study completion and publication